MEVACOR Drug Patent Profile
✉ Email this page to a colleague
When do Mevacor patents expire, and when can generic versions of Mevacor launch?
Mevacor is a drug marketed by Merck and is included in one NDA.
The generic ingredient in MEVACOR is lovastatin. There are thirty-three drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lovastatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mevacor
A generic version of MEVACOR was approved as lovastatin by ACTAVIS ELIZABETH on December 17th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEVACOR?
- What are the global sales for MEVACOR?
- What is Average Wholesale Price for MEVACOR?
Summary for MEVACOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 127 |
| Clinical Trials: | 27 |
| Patent Applications: | 4,299 |
| Drug Prices: | Drug price information for MEVACOR |
| DailyMed Link: | MEVACOR at DailyMed |
Recent Clinical Trials for MEVACOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AstraZeneca | Phase 4 |
| Heart Health Research Center | Phase 4 |
| Amgen | Phase 4 |
US Patents and Regulatory Information for MEVACOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | MEVACOR | lovastatin | TABLET;ORAL | 019643-002 | Mar 28, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck | MEVACOR | lovastatin | TABLET;ORAL | 019643-003 | Aug 31, 1987 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck | MEVACOR | lovastatin | TABLET;ORAL | 019643-004 | Dec 14, 1988 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MEVACOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck | MEVACOR | lovastatin | TABLET;ORAL | 019643-002 | Mar 28, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | MEVACOR | lovastatin | TABLET;ORAL | 019643-004 | Dec 14, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | MEVACOR | lovastatin | TABLET;ORAL | 019643-003 | Aug 31, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MEVACOR
See the table below for patents covering MEVACOR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 3062122 | ⤷ Sign Up | |
| Philippines | 16913 | HYPOCHOLESTEREMIC FERMENTATION PRODUCTS AND PROCESS OF PREPARATION | ⤷ Sign Up |
| Philippines | 16652 | HYPOCHOLESTEREMIC FERMENTATION PRODUCTS | ⤷ Sign Up |
| Zimbabwe | 13480 | HYPOCHOLESTEREMIC FERMENTATION PRODUCTS AND PROCESS OF PREPARATION | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
